1 minute read
Jan. 17, 2022

MRTX1133: A First-in-Class Oral KRAS(G12D) Inhibitor

MRTX1133

reversible KRASG12D inhibitor preclinical efficacy in cancer model from SBDD around KRASG12C inhibitor Journal of Medicinal Chemistry Mirati Therapeutics, San Diego, CA

twitterlinkedinprintemail